Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.69 |
| ▸ | ACHE | P22303 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22076347 | 0.91 | BCHE (0.66) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL20581791 | 0.91 | KDM4E (0.73) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL22076462 | 0.88 | BCHE (0.72) | BCHEACHECYP3A4MAPTALDH1A1 | |
| SCHEMBL23620834 | 0.84 | KDM4E (0.55) | BCHEACHEKDM4ECYP3A4MAPT | |
| Apigenin Triacetate SCHEMBL1676023 | 0.84 | KDM4E (0.88) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL23620836 | 0.83 | KDM4E (0.57) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL22107685 | 0.81 | MEN1 (0.60) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL22076515 | 0.81 | KDM4E (0.70) | BCHEACHEKDM4ECYP3A4MAPT | |
| SCHEMBL22076468 | 0.80 | ADORA3 (0.59) | BCHEACHEKDM4ECYP3A4ALDH1A1 | |
| SCHEMBL17138137 | 0.80 | BCHE (0.58) | BCHEACHEKDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11058698-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801489-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112367987-A | Active agents and methods for their use in treating metabolic disorders and non-alcoholic fatty liver disease | 旗舰创业创新五公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058698-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | BCHE 901/4885ACHE 1525/4885KDM4E 2430/4885 |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | BCHE 655/4885ACHE 2189/4885KDM4E 4251/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | BCHE 655/4885ACHE 2189/4885KDM4E 4251/4885 |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | BCHE 901/4885ACHE 1525/4885KDM4E 2430/4885 |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | BCHE 901/4885ACHE 1525/4885KDM4E 2430/4885 |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | ENPP2, MBOAT7, AADAC | BCHE 901/4885ACHE 1525/4885KDM4E 2430/4885 |
| US-12115178-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | ENPP2, MBOAT7, AADAC | BCHE 901/4885ACHE 1525/4885KDM4E 2430/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | BCHE 655/4885ACHE 2189/4885KDM4E 4251/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | BCHE 655/4885ACHE 2189/4885KDM4E 4251/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | BCHE 655/4885ACHE 2189/4885KDM4E 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.